{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:57:26Z","timestamp":1772499446402,"version":"3.50.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Filgotinib, a Janus kinase 1-preferential inhibitor, is approved for the treatment of moderately to severely active ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the effects of filgotinib on endo-histological outcomes and tissue RNA sequencing data from the SELECTION trial (NCT02914522).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis assessed single and composite endo-histological improvement and remission endpoints at week (W) 10 and W58 in patients with moderately to severely active UC receiving once-daily filgotinib 200\u2009mg (FIL200) or 100\u2009mg, or placebo. Post hoc RNA sequencing analysis was performed on colonic mucosal biopsies from baseline and W10. Comparisons were made between patients who did and did not achieve endo-histological outcomes at W10 and treatment arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Greater proportions of patients achieved single and composite endo-histological improvement and remission endpoints with FIL200 than placebo at W10 and W58 (endo-histological remission, W10: 6.7% vs 1.8%; P\u2009=\u20090.0021; W58: 12.1% vs 5.1%; P\u2009=\u20090.0485). Differentially expressed genes between baseline and W10 that were associated with histologic remission at W10 had upregulated and downregulated expression opposite to that of an active UC signature. Patients treated with FIL200, achieving endoscopic improvements or histological remission, exhibited reduced neutrophil-related gene expression (eg, neutrophil migration, P\u2009&amp;lt;0.0001) and enriched gene expression for mitochondrial activity and epithelial repair compared with those without (eg, PADI2, log2[fold change]\u2009=\u20092, P\u2009&amp;lt;0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Filgotinib improved endo-histological outcomes in patients with UC, with a dose-dependent effect on transcription. Gene expression changes and enriched pathways suggest that achieving endoscopic and histological endpoints in patients receiving FIL was associated with the restoration of mucosal homeostasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf228","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:33:25Z","timestamp":1768566805000},"source":"Crossref","is-referenced-by-count":0,"title":["Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"first","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto , Porto,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-9188","authenticated-orcid":false,"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich , Zurich,","place":["Switzerland"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6914-3822","authenticated-orcid":false,"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Alimentiv Inc. , London, ON,","place":["Canada"]},{"name":"Western University , London, ON,","place":["Canada"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy, F-54500,","place":["France"]},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre , Montreal, QC,","place":["Canada"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-1004","authenticated-orcid":false,"given":"Alessandra","family":"Oortwijn","sequence":"additional","affiliation":[{"name":"Alfasigma BV , Utrecht,","place":["Netherlands"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3499-9541","authenticated-orcid":false,"given":"Laure","family":"Cougnaud","sequence":"additional","affiliation":[{"name":"Open Analytics NV , Antwerp,","place":["Belgium"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2471-0494","authenticated-orcid":false,"given":"Margaux","family":"Faes","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen,","place":["Belgium"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1052-6708","authenticated-orcid":false,"given":"Yasmina","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Clinics of Respiratory Medicine, University Hospital Basel, University of Basel , Basel,","place":["Switzerland"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-8952","authenticated-orcid":false,"given":"Matthew","family":"Randall","sequence":"additional","affiliation":[{"name":"Alfasigma Schweiz AG , Zofingen,","place":["Switzerland"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7678-6519","authenticated-orcid":false,"given":"Christine","family":"Rudolph","sequence":"additional","affiliation":[{"name":"Alfasigma GmBH , Munich,","place":["Germany"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna , Vienna,","place":["Austria"]}]}],"member":"286","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026030218563461700_jjaf228-B1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","article-title":"Ulcerative colitis: an update","volume":"21","author":"Segal","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"2026030218563461700_jjaf228-B2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Dig Liver Dis"},{"key":"2026030218563461700_jjaf228-B3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026030218563461700_jjaf228-B4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1097\/MIB.0000000000001275","article-title":"Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in ulcerative colitis","volume":"23","author":"Ponte","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026030218563461700_jjaf228-B5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO position paper: harmonization of the approach to ulcerative colitis histopathology","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026030218563461700_jjaf228-B6","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.3748\/wjg.v19.i43.7552","article-title":"Mucosal healing and deep remission: what does it mean?","volume":"19","author":"Rogler","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2026030218563461700_jjaf228-B7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ecco-jcc\/jjv074","article-title":"Clinical trials in ulcerative colitis: a historical perspective","volume":"9","author":"Hindryckx","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2026030218563461700_jjaf228-B8","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis","volume":"159","author":"Yoon","year":"2020","journal-title":"Gastroenterology"},{"key":"2026030218563461700_jjaf228-B9","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.3390\/jcm10235551","article-title":"Treatment targets in ulcerative colitis: is it time for all in, including histology?","volume":"10","author":"Wetwittayakhlang","year":"2021","journal-title":"J Clin Med"},{"key":"2026030218563461700_jjaf228-B10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17474124.2024.2326838","article-title":"Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials","volume":"18","author":"Pai","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026030218563461700_jjaf228-B11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00535-023-02013-7","article-title":"Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis","volume":"58","author":"Parkes","year":"2023","journal-title":"J Gastroenterol"},{"key":"2026030218563461700_jjaf228-B12","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/ecco-jcc\/jjad087","article-title":"A comparative evaluation of the measurement properties of three histological indices of mucosal healing in ulcerative colitis: Geboes Score, Robarts Histopathology Index and Nancy Index","volume":"17","author":"Peyrin-Biroulet","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026030218563461700_jjaf228-B13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000527846","article-title":"Positioning and usefulness of biomarkers in inflammatory bowel disease","volume":"104","author":"Sakurai","year":"2023","journal-title":"Digestion"},{"key":"2026030218563461700_jjaf228-B14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/ibd\/izaa075","article-title":"Transcriptional signatures that define ulcerative colitis in remission","volume":"27","author":"Fenton","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026030218563461700_jjaf228-B15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41467-018-07841-3","article-title":"Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response","volume":"10","author":"Haberman","year":"2019","journal-title":"Nat Commun"},{"key":"2026030218563461700_jjaf228-B16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/ibd\/izab059","article-title":"Ultra-high magnification endocytoscopy and molecular markers for defining endoscopic and histologic remission in ulcerative colitis\u2014an exploratory study to define deep remission","volume":"27","author":"Iacucci","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026030218563461700_jjaf228-B17","author":"Alfasigma S.p.A","year":"2023"},{"key":"2026030218563461700_jjaf228-B18","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2026030218563461700_jjaf228-B19","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","article-title":"Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2026030218563461700_jjaf228-B20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","article-title":"Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: international Delphi consensus recommendations","volume":"18","author":"Schreiber","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026030218563461700_jjaf228-B21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ecco-jcc\/jjad018","article-title":"Filgotinib improved health-related quality of life and led to comprehensive disease control in individuals with ulcerative colitis: data from the SELECTION trial","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026030218563461700_jjaf228-B22","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026030218563461700_jjaf228-B23","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"2026030218563461700_jjaf228-B24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s43588-021-00114-y","article-title":"The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework","volume":"1","author":"Massimino","year":"2021","journal-title":"Nat Comput Sci"},{"key":"2026030218563461700_jjaf228-B25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gut.2004.049411","article-title":"Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis","volume":"54","author":"D\u2019Argenio","year":"2005","journal-title":"Gut"},{"key":"2026030218563461700_jjaf228-B26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.gastro.2020.04.018","article-title":"Evidence that pathogenic transglutaminase 2 in celiac disease derives from enterocytes","volume":"159","author":"Iversen","year":"2020","journal-title":"Gastroenterology"},{"key":"2026030218563461700_jjaf228-B27","doi-asserted-by":"crossref","first-page":"G439","DOI":"10.1152\/ajpgi.00104.2022","article-title":"DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids","volume":"323","author":"Flood","year":"2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2026030218563461700_jjaf228-B28","doi-asserted-by":"crossref","first-page":"644244","DOI":"10.3389\/fmed.2021.644244","article-title":"An IFN-STAT axis augments tissue damage and inflammation in a mouse model of Crohn\u2019s disease","volume":"8","author":"Stolzer","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026030218563461700_jjaf228-B29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/ijms25010348","article-title":"Comprehensive analysis of PANoptosis-related gene signature of ulcerative colitis","volume":"25","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026030218563461700_jjaf228-B30","doi-asserted-by":"crossref","first-page":"106831","DOI":"10.1016\/j.isci.2023.106831","article-title":"Integrative analysis reveals marker genes for intestinal mucosa barrier repairing in clinical patients","volume":"26","author":"Zhao","year":"2023","journal-title":"iScience"},{"key":"2026030218563461700_jjaf228-B31","doi-asserted-by":"crossref","first-page":"i741","DOI":"10.1093\/ecco-jcc\/jjad212.0481","article-title":"P351 The histo-endoscopic spectrum in ulcerative colitis reveals a distinct mucosal transcriptome for histo-endoscopic remission","volume":"18","author":"Lenfant","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026030218563461700_jjaf228-B32","author":"Raghavan","year":"2024"},{"key":"2026030218563461700_jjaf228-B33","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","article-title":"Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes","volume":"17","author":"Magro","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026030218563461700_jjaf228-B34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/ibd\/izae278","article-title":"Circulating biomarkers and mediators of filgotinib treatment effects in moderately to severely active ulcerative colitis","volume":"31","author":"Nakase","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026030218563461700_jjaf228-B35","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.3390\/ijms23137151","article-title":"The importance of CXCL1 in the physiological state and in noncancer diseases of the oral cavity and abdominal organs","volume":"23","author":"Korbecki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026030218563461700_jjaf228-B36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41423-020-0412-0","article-title":"Neutrophil chemoattractant receptors in health and disease: double-edged swords","volume":"17","author":"Metzemaekers","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2026030218563461700_jjaf228-B37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/1541-7786.MCR-16-0034","article-title":"Downregulation of the deiminase PADI2 is an early event in colorectal carcinogenesis and indicates poor prognosis","volume":"14","author":"Cantari\u00f1o","year":"2016","journal-title":"Mol Cancer Res"},{"key":"2026030218563461700_jjaf228-B38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000518414","article-title":"The clinical and prognostic significance of protein arginine deiminases 2 and 4 in colorectal cancer","volume":"89","author":"Gijon","year":"2022","journal-title":"Pathobiology"},{"key":"2026030218563461700_jjaf228-B39","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/gutjnl-2021-326451","article-title":"Biopsy and blood-based molecular biomarker of inflammation in IBD","volume":"72","author":"Argmann","year":"2023","journal-title":"Gut"},{"key":"2026030218563461700_jjaf228-B40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00296-023-05501-4","article-title":"JAK inhibitors improve ATP production and mitochondrial function in rheumatoid arthritis: a pilot study","volume":"44","author":"Mihaylova","year":"2024","journal-title":"Rheumatol Int"},{"key":"2026030218563461700_jjaf228-B41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and inter-cellular rewiring of the human colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"2026030218563461700_jjaf228-B42","doi-asserted-by":"crossref","first-page":"996057","DOI":"10.3389\/fmolb.2022.996057","article-title":"Molecular regulation after mucosal injury and regeneration in ulcerative colitis","volume":"9","author":"Zheng","year":"2022","journal-title":"Front Mol Biosci"},{"key":"2026030218563461700_jjaf228-B43","doi-asserted-by":"crossref","first-page":"18243","DOI":"10.1038\/s41598-021-97366-5","article-title":"Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis","volume":"11","author":"Linggi","year":"2021","journal-title":"Sci Rep"},{"key":"2026030218563461700_jjaf228-B44","doi-asserted-by":"crossref","first-page":"1102420","DOI":"10.3389\/fmed.2022.1102420","article-title":"Disease clearance in ulcerative colitis: setting the therapeutic goals for future in the treatment of ulcerative colitis","volume":"9","author":"Ramos","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026030218563461700_jjaf228-B45","doi-asserted-by":"crossref","first-page":"e2302607","DOI":"10.1002\/advs.202302607","article-title":"Hyper alpha2,6-sialylation promotes CD4(+) T-cell activation and induces the occurrence of ulcerative colitis","volume":"10","author":"Fan","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2026030218563461700_jjaf228-B46","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cgh.2024.01.026","article-title":"Biomarkers for personalizing IBD therapy: the quest continues","volume":"22","author":"Atreya","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026030218563461700_jjaf228-B47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","article-title":"Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC","volume":"67","author":"Arijs","year":"2018","journal-title":"Gut"},{"key":"2026030218563461700_jjaf228-B48","doi-asserted-by":"crossref","first-page":"e00578","DOI":"10.14309\/ctg.0000000000000578","article-title":"Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study","volume":"14","author":"Steere","year":"2023","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf228\/66540262\/jjaf228.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf228\/66540262\/jjaf228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf228\/66540262\/jjaf228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:56:48Z","timestamp":1772495808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf228\/8438346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf228","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,22]]},"article-number":"jjaf228"}}